Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
Sweeping review suggests weight-loss drugs’ effect on 175 conditions
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected but contain surprises, too.
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
GLP-1 weight-loss drugs may cut risk of dementia and other conditions
GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and dementia.
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
Ozempic and similar weight loss drugs may lower risk of 42 health conditions, but also pose risks
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1. Today, GLP-1 drugs,
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions such as substance abuse, psychosis, infections and even dementia. But these drugs also come with risks that shouldn't be overlooked,
GLP-1 Drugs Linked to Lower Alzheimer's Risk Amid Safety Warnings
A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease. Researchers at Washington University in St. Louis examined 215,
6 Common Side Effects from Taking a GLP-1 Medication—and How to Manage Them
If your constipation lasts for more than 3 days, speak with your doctor about options to help. You might need to add a stool ...
phillyvoice.com4h
Ozempic and Wegovy are helping many Americans lose weight, but they also may have other beneficial uses
News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...
GLP-1 weight loss medications pose challenges for c-stores. Here’s how retailers can respond.
Users of Ozempic and other drugs are shunning items like energy drinks and salty snacks, research shows. But there are ...
I work 3 jobs to pay for my semaglutide weight loss shots — now I’m locked in for life
Getting skinny on weight loss meds takes a fat wad of cash. And Staci Rice is working double-time for the petite payoffs.